Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy

NCT00473512 is registered in ClinicalTrials.gov with Cougar Biotechnology, Inc. as lead sponsor.

NCT NCT00473512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00473512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy
Lead sponsor
Cougar Biotechnology, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2005
Completion date
November 30, 2008
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms